License and Collaboration Agreements - Additional Information (Details) - USD ($) $ in Millions		1 Months Ended					3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Jun. 30, 2023	Mar. 31, 2023	Feb. 28, 2023	Aug. 31, 2021	Jul. 31, 2020	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2020
Preferred stock, shares issued (in shares)							0		0		0
Acquired IPR&D expense	$ 3.0								$ 0.2
Quarterly fee									1.3
Delivery fee									0.2
Completion fee									0.2
Exercise fee									$ 1.0
Accrued Upfront Fee												$ 0.2
License fees received		$ 0.2		$ 0.4
Royalty Based on Net Sales of Licensed Products, Percentage									1.00%
Royalty expense									$ 0.0
Research and Development [Member]
Quarterly fee							$ 1.3	$ 1.3	0.9	$ 3.9
Research Development And Regulatory Milestone
Potential milestone payment									18.0
Adimab Assignment Agreement [Member]
Milestone payment									3.6		$ 7.5
Advance payment									$ 7.9
Adimab Assignment Agreement [Member] | Maximum [Member]
Potential milestone payment						$ 24.6
Royalty percentage of sublicense consideration									55.00%
Adimab Assignment Agreement [Member] | Minimum [Member]
Royalty percentage of sublicense consideration									45.00%
Adimab Assignment Agreement [Member] | Research and Development [Member]
Recognized expense							0.0	0.1	$ 0.0	0.6
Adimab Assignment Agreement [Member] | Acquired In Process Research And Development Expense [Member]
Milestone payment			$ 0.4				3.2		3.6
Adimab Assignment Agreement [Member] | First Product [Member]
Potential milestone payment						16.5
Adimab Assignment Agreement [Member] | Second Product [Member]
Potential milestone payment						$ 8.1
Adimab Assignment Agreement [Member] | Research Development And Regulatory Milestone
Milestone payment									11.1
Adimab Collaboration Agreement [Member]
Expenses							0.1	0.3	0.5	1.3
Adimab Collaboration Agreement [Member] | Research and Development [Member]
Quarterly fee							1.3	1.3	3.9	3.9
Delivery fee								0.0		0.2
Adimab Collaboration Agreement [Member] | Acquired In Process Research And Development Expense [Member]
Delivery fee							1.0	1.0	0.2	1.0
Adimab Platform Transfer Agreement [Member] | Research Development And Regulatory Milestone
Potential milestone payment									9.5
Cell Line License Agreement [Member]
Acquired IPR&D expense							0.0		0.6
TSRI
Research and development expenses							$ 0.0	$ 0.0	$ 0.0	$ 1.7
Amount Paid As Pre Paid Funding For Research Plan					$ 1.5